EXPRESSION OF P FALCIPARUM LSA-1 SUBUNITS
Agency: Department of Health and Human Services
Agency Tracking Number: 1R43AI047506-01A1
Phase: Phase I
Awards Year: 2001
Solitcitation Year: N/A
Solitcitation Topic Code: N/A
Solitcitation Number: N/A
Small Business Information
HAWAII BIOTECHNOLOGY GROUP, INC.
99-193 AIEA HEIGHTS DR, STE 236, AIEA, HI, 96701
Hubzone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: N
Name: DAVID CLEMENTS
Phone: () -
Phone: () -
Phone: (808) 486-5333
AbstractDESCRIPTION: (Adapted from Applicant's Abstract) Malaria is a tropical parasitic disease that is a significant health threat. Each year, approximately 500 million people become infected and 2 to 3 million die worldwide. There is a great need to control the spread of this disease. Recently, the development of malaria vaccines has focused on the use of recombinant DNA technology. The inclusion of pre-erythrocytic antigens, such as the liver stage antigen-1 (LSA-1), is important in the development of a successful multi-component malaria vaccine. To date, most efforts to develop LSA-1-based vaccines have focused on the use of defined peptide sequences. Phase I research will test the feasibility of efficiently expressing truncated forms of the Plasmodium falciparum LSA-1 antigen. These recombinant subunits have the potential to provide a broader immune response than the synthetic peptides tested. The expression system proposed for this research has been shown to express high levels of recombinant proteins, including a malaria erythrocyte stage vaccine candidate antigen. The successful expression of high levels of a liver stage candidate vaccine antigen with appropriate antigenic and immunogenic characteristics could contribute to the development of a safe, efficacious and cost effective vaccine for malaria. PROPOSED COMMERCIAL APPLICATION: Malaria poses a significant health threat. Annually, approximately 500 million people become infected and 1 to 2 million die. Currently, there is no vaccine for malaria. The proposed research will test the feasibility of expressing and secreting a malaria subunit targeted for vaccine development. Successful expression of high levels of this subunit could contribute to the development of a safe, efficacious and cost effective malaria vaccine.
* information listed above is at the time of submission.